Adverse events reporting in stage III NSCLC trials investigating surgery and radiotherapy.
Thomas IseliThierry BerghmansMarkus GlatzerAchim RittmeyerGilbert MassardValerie DurieuxThomas BuchsbaumPaul Martin PutoraPublished in: ERJ open research (2020)
Overall, AE reporting in stage III NSCLC was inconsistent and inhomogeneous. Studies including surgical study arms often reported only treatment-related deaths in regards of surgical AEs. Underreporting of AEs prohibits the extraction of patient-relevant information for decision-making and represents a suboptimal use of invested resources.
Keyphrases
- small cell lung cancer
- decision making
- advanced non small cell lung cancer
- adverse drug
- minimally invasive
- early stage
- coronary artery bypass
- case report
- radiation therapy
- health information
- squamous cell carcinoma
- epidermal growth factor receptor
- atrial fibrillation
- social media
- acute coronary syndrome
- case control
- combination therapy
- percutaneous coronary intervention
- drug induced
- electronic health record